Moderna Stock Plunges 25% After Possible Cancer Vaccine Data Leak

The Quick Take
The drop is a sharp reversal of a massive 2026 stock rally fueled by optimism over its personalized cancer vaccine.
Ground Level News gathers headlines from public news feeds. This page shows a short summary only; the full article and all rights belong to Forbes.


